Ivonescimab Beats Keytruda on Overall Survival in Chinese Lung Cancer Trial
SMMT sits 24% above its 52-week low of $12.07.
Summary
Akeso's Phase III HARMONi-2 trial in China showed ivonescimab monotherapy achieved a statistically significant overall survival benefit versus pembrolizumab in PD-L1-positive advanced NSCLC. This is the first OS readout from this head-to-head trial, building on the previously reported PFS advantage (HR 0.51). The result strengthens the case for ivonescimab's differentiation from Keytruda, though the data are from a China-only study and the drug remains unapproved in Summit's territories. The FDA decision on the HARMONi BLA is set for November 14, 2026, and this OS data could influence regulatory discussions and commercial positioning. Summit's cash runway remains tight, but positive data may support its ongoing ATM program.
At the time of this announcement, SMMT was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $12.07 to $29.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.